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The bulk of current HIV vaccine research is conducted within the infectious disease par-
adigm that has been very successful in developing vaccines against many other viral
diseases. Different HIV vaccine concepts, based on the induction of neutralizing antibod-
ies and/or cell mediated immunity, have been developed and clinically tested over the last
30 years, resulting in a few small successes and many disappointments. As new scientific
knowledge is obtained, HIV vaccine concepts are constantly modified with the hope that
the newly introduced tweaks (or paradigm drifts) will provide the solution to one of the
most difficult challenges that modern biomedical research is confronting. Efficacy trials
have been critical in guiding HIV vaccine development. However, from the five phase III
efficacy trials conducted to date, only one (RV144) resulted in modest efficacy.The results
from RV144 were surprising in many ways, including the identified putative correlates of
protection (or risk), which did not include neutralizing antibodies or cytotoxic T-cells. The
solution to the HIV vaccine challenge may very well come from approaches based on the
current paradigm. However, at the same time, out-of-the-paradigm ideas should be sys-
tematically explored to complement the current efforts. New mechanisms are needed to
identify and support the innovative research that will hopefully accelerate the development
of an urgently needed HIV vaccine.
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KUHN’S VIEWS OF NORMAL SCIENCE AND PARADIGM
CHANGE
The bulk of the current scientific activity, at least the one that it is
publically funded, is generally conducted within what is known as
normal science.
The term “normal science” was proposed by Thomas Kuhn
in his 1962 book entitled “The Structure of Scientific Revolutions”
(1). In his book, Kuhn describes normal science as the “research
that it is firmly based upon one or more past scientific achieve-
ments, achievements that some particular scientific community
acknowledges for a time as supplying the foundation for its further
practice.”Those past achievements are generally well-documented
in the scientific literature, and serve “to define the legitimate prob-
lems and methods of a research field for succeeding generations of
practitioners.” In addition, Kuhn coined the term “paradigm” to
define the achievements that were “sufficiently unprecedented to
attract an enduring group of adherents”and at the same time,“suf-
ficiently open ended to leave all sorts of problems for the redefined
group of practitioners to resolve.”
Normal science produces much useful information, but Kuhn
proposed that normal science results in little major novelties and
it could be argued that it is mostly gap-filling science. Unexpected
results that cannot be explained by the current paradigm are fre-
quently ignored or dismissed. When the paradigm is incapable of
producing a solution, it enters into a crisis, this leading to a “para-
digm shift” which changes the basic assumptions within the ruling
theory of science. Then, under the light of a more satisfactory
paradigm, some of the previously dismissed observations are
acknowledged and understood, and new avenues are opened to
conduct new research and to finally solve the problem.
CURRENT HIV VACCINE PARADIGM AND DRIFTS THAT HAVE
OCCURRED OVER THE PAST 30 YEARS
Although it is not straightforward to formally define the current
HIV vaccine development paradigm, it is not very different from
the one that started in the late 1800s, when the germ theory of
disease was formulated (2). In summary, the infectious disease
vaccine paradigm proposes that different germs cause different dis-
eases, and that the protective adaptive immune responses resulting
from the disease can also be stimulated by weakened (attenuated)
or killed (inactivated) microorganisms in the form of vaccines.
This paradigm has been extremely successful in defining the eti-
ology of major killer diseases of mankind. It has also resulted in
the development of vaccines and drugs against many infectious
diseases.
However, the infectious disease paradigm, like many other
satisfactory paradigms, has gone through minor changes (or par-
adigm drifts). One change occurred when viruses were described
as being structurally different from bacteria, although that did
not prevent Louis Pasteur from empirically developing a rabies
vaccine, even before viruses were formally discovered (3). In the
1970s retroviruses were widely acknowledged as the cause of can-
cer and leukemia in animals, but there was strong reluctance to
accept the idea that retroviruses could cause infections in humans.
When Robert Gallo and collaborators proposed in 1979 that a new
retrovirus, the human T-cell lymphoma virus 1 (HTLV-1), causes
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adult T-cell leukemia (ATL), he found resistance to have the paper
accepted for publication, because it represented a departure from
the commonly accepted science (4, 5). Fortunately, the common
science that was conducted in the 1970s under the “War on Can-
cer” Program (6) developed the basic tools of retrovirology that
also allowed the rapid isolation and characterization of the human
immunodeficiency virus (HIV) soon after AIDS was recognized as
a new disease in 1981. This is a remarkable example of how research
supported to solve a given problem (cancer in this case) can yield
unanticipated results in another field (AIDS). What is important
is to always keep an open mind.
The decades of the 60s and 70s witnessed the birth of mod-
ern molecular biology (7) and rapid progress was made in the
understanding of the structure–function relationships in animal
viruses. German virologists made many of the pioneering discov-
eries (8), especially the school of Werner Schäfer (1912–2000) at
the Max-Planck-Institut fúr Virusforschung in Tubingen. Study-
ing fowl plague virus (FPV) and other influenza A viruses, Schäfer
and collaborators established that the haemaglutinin (HA) serves
as a ligand during attachment of the virus cellular receptor and that
it was also the immunogen which induces the production of pro-
tective neutralizing antibodies in the infected host. Schäfer went
on to say in 1963 that “the finding that the immunizing capacity
of the fowl plague virus resides in its hemagglutinin shell material
led to the proposal to use, instead of inactivated total virus the iso-
lated hemagglutinin of influenza and possibly other myxoviruses
as vaccines” (9).
Although we cannot consider this proposed subunit approach
as a completely new paradigm, it was obviously a major depar-
ture (a paradigm drift) from how viral vaccines were successfully
developed until then, based on inactivated or attenuated viruses.
It is interesting that two American scientists who were to occupy
important roles in the early HIV vaccine effort in the United States,
Dani Bolognesi (a virologist from Duke University who became the
co-chair of the US government’s AIDS Vaccine Working Group)
and Peter Fischinger (who became the first AIDS Coordinator
from the US Department of Health and Human Services), had
worked with Werner Schäfer in Tubingen, studying the structure–
function relationship in animal retroviruses (10). They quickly
translated those concepts to the search for an HIV vaccine (11,
12), confirming that the envelope glycoprotein of HIV was suffi-
cient to induce the production of neutralizing antibodies, as it has
been shown earlier with the myxoviruses (13).
Since HIV is a very dangerous pathogen, the prospect of using
a subunit vaccine was daunting, both in relation to manufacturing
issues and because of potential risks to the vaccinated individu-
als. The response to this challenge was provided by the emerging
science of genetic engineering and recombinant DNA technology,
which provided the possibility of manufacturing large amounts
of viral proteins without actually growing the virus. The most
relevant precedent at that time was that of the vaccine against
the hepatitis B virus. A highly effective plasma-derived hepatitis
B vaccine had been licensed by the US Food and Drug Admin-
istration (FDA) in 1981. However, concerns were rapidly raised
because the source of the vaccine immunogen was the plasma of
individuals who could also be carrying the AIDS virus. The solu-
tion came when the surface antigen of the hepatitis B virus was
successfully cloned and expressed in yeast, allowing for the manu-
facturing of a recombinant hepatitis B vaccine, which was licensed
in 1986 (14, 15).
Thus, the first wave of HIV vaccine development, based on
genetically engineered subunit envelope vaccines (16), was based
on several past achievements of normal science: (a) the demonstra-
tion that the envelope glycoproteins of the virus are sufficient to
induce neutralizing antibodies; (b) the ability to manufacture large
amounts of these proteins by genetic engineering techniques; and
(c) the successful proof of concept provided by the recombinant
hepatitis B vaccine.
This initial vaccine effort also benefited from rapid advances
in the molecular biology of HIV that occurred within 5 years
after its discovery, including the identification of the major struc-
tural proteins of the virus, the cloning and sequencing of the HIV
genome, early information on the genetic variability of different
virus strains, the description of neutralizing antibodies, and the
development of the first non-human primate models (17).
Although in the late 1980s nobody knew for sure how long it
would take to develop an HIV vaccine, it is also fair to say that
the field was generally optimistic. The prediction was made, and
repeated many times since then, that an HIV vaccine would be
available within the next 10 years. However, no one knew at that
time that HIV/AIDS was much more complex than any other viral
disease for which vaccines had been successfully developed (18–
21). Nevertheless, phase I clinical trials of HIV envelope vaccines
started in the United States in 1988, thus beginning a long history
of small successes and big disappointments.
In previous articles, I have discussed in detail the three major
approaches that have been explored over the last 30 years in trying
to develop an HIV vaccine (17, 22). Although I have described
those three waves of vaccine approaches and clinical trials as
based on three different paradigms, in fact they only represented
allowable tweaks (or drifts) within the overarching infectious dis-
ease paradigm. The first wave started around 1984 and it was
based on the concept that neutralizing antibodies would be suf-
ficient to confer protection against HIV infection. This led to the
development of numerous recombinant envelope-based candidate
vaccines that were tested in clinical trials. This first wave came to
an end in 2003, with the negative results from two efficacy trials
designed to evaluate the protective efficacy of the gp120 vaccines
from VaxGen (23, 24). The second wave began with the recog-
nition in the early 2000s of the critical importance of CD8+
T-cell responses in the control of HIV infection, and this led to
the development and refinement of live recombinant viral vec-
tors, especially poxvirus and adenovirus vectors, as well as DNA
vaccines. This period was formally concluded in 2007 with the
unexpected lack of efficacy in the STEP trial, which evaluated a
cell-mediated immunity vaccine based on an adenovirus type 5
(Ad5) vector (25). The third wave may have started in 2009 with
the modest efficacy obtained in the RV144 trial conducted in Thai-
land, to evaluate a prime boost combination of an ALVAC vector
followed by an envelope glycoprotein (26). This wave, that hope-
fully will take us to the development of an effective vaccine, should
learn from past failures and systematically explore different alter-
natives, including novel concepts that do not fall within the current
paradigm.
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However, it is fair to say that the first two waves just described
(antibodies and cell-mediated immunity) have not completely
ended. Instead, they are constantly revisited when new knowl-
edge is obtained, and numerous adjustments have been made,
representing allowable drifts within the current paradigm, with
the hope that those changes would eventually led to the solution
of the problem.
For example, one of the first conceptual drifts in the anti-
body approach occurred around 1994 with the realization that
laboratory-adapted strains of HIV behave immunologically differ-
ently from the primary/clinical isolates (27). That paradigm drift
led to the design of more sophisticated envelope immunogens,
such as those based on founder/transmitted viruses (28) or those
using envelope trimers rather than the gp120 monomers initially
used to develop HIV candidate vaccines (29, 30). It is also relevant
to mention here that the hope of designing epitope-based HIV
vaccines started as early as 1989, when the V3 loop of gp120 was
thought to be, and even referred to, as the Principal Neutraliza-
tion Domain (PND) (31), a vaccine concept that even progressed
to phase I clinical trials (32). That early peptide-based HIV vac-
cine approach was eventually abandoned when it was realized that
complex conformational epitopes are important for the induction
of neutralizing antibodies (33).
However, a major driver of the more recent approaches in
the antibody field has been the need to deal with the immuno-
logical variability of HIV strains and clades. The discovery that
broadly neutralizing antibodies recognize defined epitopes in the
envelope trimer, which has led to a renewed effort to develop
epitope-based vaccines guided by structural biology (34, 35), a
reductionist approach that claims to have achieved proof of con-
cept with the respiratory syncytial virus (36), but which has been
strongly criticized by others (37, 38). The difficulties in designing
an epitope-based vaccine capable of eliciting broadly neutraliz-
ing antibody responses is compounded by the extensive affinity
maturation process that anti-HIV neutralizing antibodies undergo
before acquiring the broadly neutralizing characteristics (39). This
challenge is being addressed by the use of sequential immuniza-
tion with different HIV envelope immunogens designed to guide
the evolution of the antibody, triggering the selection and expan-
sion of germline precursor and intermediate memory B cells
to recapitulate B cell ontogenies associated with the maturation
of a broadly neutralizing antibody response (40, 41), a concept
that had been proposed several years before (42). Others, per-
haps more practical approaches, have been proposed to develop
a globally relevant HIV vaccine capable of protecting against a
variety of strains and clades (43), including the use of mosaic
immunogens (29, 44).
On the other hand, most of the paradigm drifts in the field of
cell-mediated HIV vaccines have focused on the use of different
vectors, or prime-boost approaches, with the object of eliciting
stronger and more functional CD8+ responses to selected HIV
proteins (45–47). Perhaps, the most significant paradigm drift
in the cell-mediated immunity field is represented by the report
that the early control elicited by a simian immunodeficiency virus
(SIV) protein-expressing rhesus cytomegalovirus (RhCMV) vec-
tors (48) was due to SIV-specific CD8+ effector memory T cells
that recognize unusual, diverse, and highly promiscuous epitopes,
including dominant responses to epitopes restricted by class II
major histocompatibility complex (MHC) molecules (49–51).
EFFICACY TRIALS HAVE BEEN INSTRUMENTAL IN DRIFTING
PARADIGMS AND ADVANCING VACCINE RESEARCH
In the absence of predictive animal models, or of known immune
correlates of protection, the only approach to assess the protective
efficacy of any HIV vaccine concept is by conducting large scale
efficacy trials of the candidate vaccines considered to be the most
promising. However, what is considered to be the “most promis-
ing” candidate vaccines usually is in the eyes of the beholder. Since
efficacy trials are complex and expensive, it is widely recognized
that a decision to proceed to phase III trials needs to be based
on the best science available, and this responsibility should not be
taken lightly. On the other hand, the urgent public health need of
an HIV vaccine should be considered in order not to delay those
important decisions (52).
A case in point is the RV144 efficacy trial conducted in Thai-
land between 2003 and 2009. The trial was strongly opposed by
a group of respected scientists, who were not convinced of its
scientific merits (53). Anyway, the trial went ahead and it was con-
ducted almost totally ignored by the scientific community. When
the announcement was made in 2009 that the RV144 trial showed
modest efficacy (26), it came as a surprise and the results were ini-
tially received with skepticism. After all, the results contradicted
what was commonly accepted at that time, namely that the most
likely protection that a vaccine could provide was against virus
load and not against virus acquisition. In addition, the identified
immune correlates of protection were not the usual suspects (neu-
tralizing antibodies or CD8+ T cells). Instead, a still to be better
defined non-neutralizing antibody response to the V1–V2 loops of
gp120 was found to be the strongest correlate of protection (54).
Subsequent laboratory studies have strengthened the conviction
that the protective efficacy observed in RV144 is true, and have
identified IgG3 antibodies as an additional potential correlate of
protection (55).
The results from the RV144 trial have stimulated new research
on antibody functions other than neutralization, such as antibody-
dependent cell-mediated cytotoxicity (ADCC) (56, 57), which is
slowly becoming part of the accepted normal science in HIV vac-
cine research, side by side with the better understood neutralizing
antibodies. The newly acquired respectability of ADCC should
help understanding the earlier results reported by Robert Gal-
los’s team in 2007 using subunit immunogens designed to raise
humoral responses against CD4-induced (CD4i) epitopes (21, 58,
59). Even earlier, in 2005, ADCC was reported as an immune
correlate of protection against SIV in non-human primate pro-
tection (60). However, the results from those experiments were
received with skepticism or even indifference, because at that time
our minds were not prepared to think outside of the box regard-
ing antibody functions. The classical neutralizing antibodies are
probably the most important mechanism of protection against
HIV, as is the case with most viral vaccines, but the potential role
of ADCC and of other antibody functions should not be dismissed
a priori (61, 62).
From the five efficacy trials of HIV vaccines that have been
completed in the last 10 years, only RV144 showed efficacy, albeit
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modest (17, 23–26, 63). To build on the success of the RV144 trial, a
group of organizations established the Pox-Protein Public-Private
Partnership (P5) to evaluate potentially improved pox-protein
vaccines to determine if they might provide significant public
health benefit, with follow-up clinical studies using improved vac-
cine regimens being planned in southern Africa and Thailand (64).
A very important objective of the P5 is to validate the hypothe-
sis that in the RV144 trial, antibodies directed against the V1–V2
loops may have contributed to protection against HIV-1 infection,
whereas high levels of envelope-specific IgA antibodies may have
mitigated the effects of protective antibodies (54). What is now
critical is to develop strict and credible go/no-go criteria to deter-
mine if the potentially improved vaccines should move from phase
I clinical trials to large scale efficacy evaluation, including the abil-
ity to test the hypotheses generated by the RV144 trial. In making
that decision, it is important to keep in mind that the RV144 trial
was conducted in Thailand in a population with relatively low risk
behavior and an annual HIV incidence of approximately 0.2% (65,
66), and that the proposed P5 trials are planned to be conducted
in populations with annual HIV incidences in the order of 3–9%.
One could argue that the vaccines to be tested by the P5 collabora-
tors should be proportionally improved, considering the stronger
force of infection in the proposed new testing population.
Since phase III efficacy trials are large and expensive, every effort
should be made to obtain pre-clinical and early clinical evidence
to justify such a decision. Although non-human primate protec-
tion experiments are instructive, and a positive result would add
confidence to a decision to move to efficacy evaluation, they are
not necessarily considered as predictive of results in humans. An
alternative, or rather complementary approach to select candidate
vaccines for further evaluation, has been proposed by testing can-
didate vaccines in a handful of human volunteers whose immune
system is intensively interrogated in the search for clues that may
suggest the induction of protective immunity. These small trials,
referred by some as “Experimental Medicine” (EM) trials, could
be very valuable for vaccines for which we have known immune
correlates of protection (67), but they present a challenge for HIV.
However, we can imagine that envelope immunogens designed to
induce broadly neutralizing antibodies, including approaches that
guide their maturation, could be tested in EM trials (40). Like-
wise, human CMV vectors could be tested in EM trials to assess
if they recapitulate in humans the potentially protective immune
responses that have been identified in rhesus monkeys (49).
Perhaps, the identification of a single protective epitope or of a
single immune correlate of protection is an illusion derived from
our desire to reduce complex biological phenomena to simple
explanations and approaches. Rather than thinking about just one
individual immune correlate, we should seriously consider that
protection is associated with a more complex immunological sig-
nature of immune responses. Fourteen years ago, Neil Nathanson
and Bonnie Mathieson, from the Office of AIDS Research of the
US National Institutes of Health, speculated that a “possible expla-
nation for the inconsistent conclusions from studies of SIV and
SHIV models is that protection does not correlate with any single
immune response but is conferred by a barrier created by the sum
of several immune defenses” (68). In fact, the coordinated activity
of multiple antibody functions has been recently suggested as the
mechanism of protection in a proposed globally relevant HIV-1
mosaic vaccine (44).
CANWE IDENTIFY INNOVATION WHENWE SEE IT?
There is no doubt that many of the paradigm drifts introduced
over the years to the original antibody and cell-mediated immu-
nity concepts have been very innovative, although they have not
represented significant shifts of the prevailing paradigm. Scien-
tists have stubbornly pursued their belief that the current para-
digm, once it is appropriately modified, will provide the solution.
Resilience is important for the progress of science. However, and
paraphrasing the immunologist and Nobel Prize winner Peter
Medawar, “the intensity of the conviction that a hypothesis is
true has no bearing on whether it is true or not” (69). Never-
theless, Medawar emphasized that the strength of the scientists’
convictions is important if only because that conviction provides
the necessary incentive to conduct the research to find out if the
hypothesis is correct.
The scientific community is generally open to accept innova-
tion when it falls within the accepted paradigms of normal science.
However, the same community is often reluctant to accept ideas
that fall outside of the paradigm. The possible reasons for this
attitude are that most of those out-of-the paradigm ideas are: (a)
sometimes proposed without much preliminary data, (b) not sup-
ported by a community of peers and, (c) in many cases, cannot
stand up to critical scrutiny or to experimental verification.
The question that we are now trying to answer is if after 30 years
of intense work, the current paradigm to develop an HIV vac-
cine is entering into a crisis, thus requiring a paradigm shift. Is
it sufficient to go back to the same drawing board every time
we experience a major failure? (70), or should we explore more
systematically completely new avenues of research? Perhaps the
nature of HIV and AIDS, which significantly differ from other
viral diseases for which vaccines have been developed, provides
the explanation for the repeated failures in our attempts to stick
to the current approaches (18–20). Perhaps, the current paradigm
is not appropriate to develop vaccines for a virus that profoundly
affects the immune system of the host and that uses many dif-
ferent mechanisms to escape what otherwise could be protective
immune responses.
A related question is if we have in place the appropriate mech-
anisms to identify and support the highly innovative science that
could allow for a paradigm shift? The current peer review system,
which has been extremely efficient in protecting the quality of
normal science, may not be the best system to stimulate out-of-the-
paradigm research, with innovative concepts placed at high risk of
being suppressed (71, 72). This challenge has been recognized by
different institutions, leading to the creation of special initiatives
to stimulate innovation on HIV vaccine research. These include
the Innovation Grant Program for Approaches in HIV Vaccine
Research created by in 1997 by the so-called Baltimore Committee
of the National Institute of Allergy and Infectious Diseases (73,
74), the Grand Challenge on Global Health Program from the Bill
& Melinda Gates Foundation (75), and the Innovation Fund from
the International AIDS Vaccine Initiative (IAVI) (76). Unfortu-
nately, those programs, that have (or had) their own mechanisms
to select and monitor projects, by and large have failed to spur
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the necessary innovation. The problem has been that it is very
difficult to predict what innovative projects will work, or even to
suggest any specific areas of exploration. However, what it is pos-
sible is to formally establish innovative processes and mechanisms
to support such research.
In 2007, the Wellcome Trust and the Bill & Melinda Gates Foun-
dation convened a meeting in London to discuss the need to bring
additional innovation to HIV vaccine research. The group rec-
ognized that innovative proposals are high-risk, that peer review
is conservative and risk adverse, and that peer-review can’t deal
with proposals that challenge accepted thinking. In considering
innovative research, the group recommended that funders con-
sider using broad-minded people who look at impact and at the
big picture, ask thoughtful questions, and give applicants a chance
to reply (77).
It is fair to say that that innovative HIV vaccine concepts that are
not part of the mainstream thinking are regularly published. Very
often those articles are initially rejected in more prestigious jour-
nals, and the authors usually struggle to secure the funds needed
to advance the research and to eventually confirm and expand,
or to refute the original observations. For instances, in 2012 Jean-
Marie Andrieu and collaborators reported that oral immunization
of chinese Rhesus macaques with a combination of Lactobacilus
plantarum and inactivated SIV provided strong protection against
subsequent infection with the virus (78, 79). More surprisingly, the
observed protection did not correlate with any known adaptive
immune response, but instead it correlated with CD8+ regula-
tory T cells that seemed to mediate a tolerogenic mechanism that
falls outside of the current paradigm. Not surprisingly, the authors
experienced difficulties in getting the paper accepted by different
journals, and the results were received with a great deal of skepti-
cism. Fortunately, the Bill & Melinda Gates Foundation was able
to support an independent confirmation of those observations. At
least in this case, a potentially game-changing idea was not dis-
missed a priori, and the results of the potentially confirmatory
study will be available at the end of 2015.
Although it is beyond my individual predictive abilities to iden-
tify what could be the most promising out-of-the-paradigm con-
cepts, a few additional examples could be listed for further explo-
ration. One is the use of HIV-1 gp-41 subunit virosomes, which
have been shown to be protective in non-human primate mod-
els, with protection correlating with mucosal antibodies rather
than with circulating neutralizing antibodies (80–83). Another
vaccine concept, also based on a gp41 peptide, was reported to
protected CD+ T cells from lysis by natural killer cells, without
having any protective effect against the infection per se (84, 85).
Finally, although whole inactivated vaccines were extensively tested
in the past in animal models, with negative results, perhaps it is not
unreasonable to revisit this concept using current experimental
approaches, including low-dose repeated challenges (86).
The barriers to accept new concepts or paradigms cannot be
underestimated. This was well understood by the German theo-
retical physicist Max Planck when he said that “a new scientific
truth does not triumph by convincing its opponent and making
them see the light, but rather because its opponents eventually die,
and a new generation grows up that is familiar with it” (from Max
Planck’ Scientific Autobiography, cited by Kuhn) (1).
DOWE NEED A NEW SCIENTIFIC PARADIGM TO FINALLY
DEVELOP AN HIV VACCINE?
The answer to that question is: perhaps. The important point
is that, while we continue pursuing the current approaches,
we should also actively explore new avenues, leaving no stone
unturned in our search for an HIV vaccine (87).
After all, 30 years of intense HIV vaccine research has not
resulted in a practical effective vaccine, although such vaccine is
sorely needed to bring the HIV epidemic under control (52). In
order to accelerate the development of an HIV vaccine, we recently
proposed a number of actions, including the suggestion to estab-
lish a program of truly innovative research with protected funding
to explore out-of-the-paradigm approaches, perhaps allocating to
this program not less than 10% of the total HIV vaccine investment
(22). Innovative research, especially out of the paradigm frame,
needs to be supported by an innovation ecosystem which should
include, not only the innovative scientists, but also an enlightened
leadership in the field, the appropriate mechanism for the selection
of projects and, perhaps more importantly, a supportive scientific
community (88).
HIV vaccine research needs to continue with the sense of
urgency that the severity of the AIDS pandemic is imposing on
us. We constantly need to keep in mind that the objective of our
research is not only the acquisition of new knowledge, but the
developing of a practical solution for one of the worse public
health problems of our time.
ACKNOWLEDGMENTS
The author thanks Marc van Regenmortel for providing construct-
ing criticisms and helpful comments.
REFERENCES
1. Kuhn TS. The Structure of Scientific Revolutions. Chicago: University of Chicago
Press (1962).
2. Richmond PA. The germ theory of disease. Henry E Sigerist Suppl Bull Hist Med
(1980) 4:84–98.
3. Smith KA. Louis pasteur, the father of immunology? Front Immunol (2012) 3:68.
doi:10.3389/fimmu.2012.00068
4. Gallo RC. The discovery of the first human retroviruses: HTLV-1 and HTLV-2.
Retrovirology (2005) 2:17. doi:10.1186/1742-4690-2-S1-S17
5. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection
and isolation of type C retrovirus particles from fresh and cultured lymphocytes
of a patient with cutaneous T-cell lymphomas. Proc Nat Acad Sci U S A (1980)
77:7415–9. doi:10.1073/pnas.77.12.7415
6. DeVita VT. A perspective on the war on cancer. Cancer J (2002) 5:352–6.
doi:10.1097/00130404-200209000-00002
7. Judson HC. The Eight Day of Creation – the Makers of the Revolution in Biology.
New York: Simon and Schuster (1979).
8. Rott R. The post-Loeffler-Frosch era: contribution of German virologists. In:
Calisher CH, Horzinek MC, editors. 100 Years of Virology: The Birth and Growth
of a Discipline. Vienna: Springer (1999). p. 43–61.
9. Schäfer W. Structure of some animal viruses and significance of their compo-
nents. Bacteriol Rev (1963) 27:1–17.
10. Ihle JN, Collins JJ, Lee JC, Fischinger PJ, Moenning V, Schäfer W, et al. Char-
acterization of the immune response to the major glycoprotein (gp 71) of
Friend leukemia virus. I. Response in BALB/c mice. Virology (1976) 75:74–87.
doi:10.1016/0042-6822(76)90008-8
11. Bolognesi DP, Fischinger PJ. Prospects for treatment of human retrovirus-
associated diseases. Cancer Res (1985) 45:470s–5s.
12. Fischinger PJ, Gallo RC, Bolognesi DP. Toward a vaccine against AIDS: rationale
and current progress. Mt Sinai J Med (1986) 53:639–47.
13. Robey WG, Arthur LO, Matthews TJ, Langlois A, Copeland TD, Lerche NW, et al.
Prospects for prevention of human immunodeficiency virus infection: purified
www.frontiersin.org March 2015 | Volume 6 | Article 124 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Esparza Paradigm change in HIV vaccines
120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad
Sci U S A (1986) 83:7023–7. doi:10.1073/pnas.83.18.7023
14. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly
of hepatitis B virus surface antigen particles in yeast. Nature (1982) 298:347–50.
doi:10.1038/298347a0
15. McAleer WC, Bynak EB, Maigetter RZ, Wampler DE, Miler WJ, Hileman
MR. Human hepatitis from recombinant yeast. Nature (1984) 307:178–80.
doi:10.1038/307178a0
16. Fischinger PJ, Robey WG, Koprowsky H, Gallo RC, Bolognesi D. Current
status and strategies for vaccines against diseases induced by human T-
cell lymphotropic retroviruses (HTLV-I, -II, -III). Cancer Res (1985) 45(9
Suppl):4694s–9s.
17. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine.
Vaccine (2013) 31:3502–18. doi:10.1016/j.vaccine.2013.05.018
18. Esparza J, Russell N, McCutchan F. The long road to an HIV vaccine. In: Klein-
man DL, Delbourne J, Cloud-Hansen KA, Handelsman J, editors. Controversies
in Science and Technology. (Vol. 3), New York, NY: Mary Ann Liebert Inc Pub-
lishers (2010). p. 44–76.
19. Lewis GK, DeVico AL, Gallo RC. Antibody persistence and T-cell balance: two
key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A
(2014) 111:15614–21. doi:10.1073/pnas.1413550111
20. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, et al. Acti-
vated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition
in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A (2015)
112:518–23. doi:10.1073/pnas.1407466112
21. Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, et al. Balance of cel-
lular and humoral immunity determines the level of protection by HIV vaccines
in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A (2015)
112(9):E992–9. doi:10.1073/pnas.1423669112
22. Esparza J. What has 30 years of HIV vaccine research taught us? Vaccines (2013)
1:513–26. doi:10.3390/vaccines1040513
23. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF,
et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vac-
cine to prevent HIV-1 infection. J Infect Dis (2005) 191:654–65. doi:10.1086/
428404
24. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F.
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recom-
binant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok,
Thailand. J Infect Dis (2006) 194:1661–71. doi:10.1086/508748
25. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Effi-
cacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study):
a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet
(2008) 372:1881–93. doi:10.1016/S0140-6736(08)61591-3
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris
R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med (2009) 361:2209–20. doi:10.1056/NEJMoa0908492
27. Bolognesi DP, Matthews TJ. HIV vaccines viral envelope fails to deliver? Nature
(1999) 391:638–9. doi:10.1038/35504
28. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med (2012)
2(11):1–23. doi:10.1101/cshperspect.a006965
29. Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM, et al. Charac-
terization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol
(2014) 88:9538–52. doi:10.1128/JVI.01739-14
30. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, et al. Differ-
ential binding of neutralizing and non-neutralizing antibodies to native-like
soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.
Retrovirology (2014) 11:41. doi:10.1186/1742-4690-11-41
31. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, et al. Prin-
cipal neutralizing domain of the human immunodeficiency virus type 1 enve-
lope protein. Proc Natl Acad Sci U S A (1989) 86:6768–72. doi:10.1073/pnas.86.
17.6768
32. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, et al. International clinical
trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine
evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac
J Allergy Immunol (1997) 15:105–13.
33. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL. Neutralization of divergent
HIV-1 isolates by conformation-dependent human antibodies to gp120. Science
(1991) 254:105–8. doi:10.1126/science.1718036
34. Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly
neutralizing antibodies to HV-1. Cold Spring Harb Perspect Med (2011)
1(1):a007278. doi:10.1101/cshperspect.a007278
35. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A
blueprint for HIV vaccine discovery. Cell Host Microbe (2012) 12:396–407.
doi:10.1016/j.chom.2012.09.008
36. McLellan JS, Correia BE, Chen M, Yang Y, Graham BS, Schief WR, et al.
Design and characterization of epitope-scaffold immunogens that present
the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011)
409:853–66. doi:10.1016/j.jmb.2011.04.044
37. Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reduc-
tionist thinking. Front Immunol (2012) 3:194. doi:10.3389/fimmu.2012.00194
38. Van Regenmortel MH. An outdated notion of antibody specificity is one of the
major detrimental assumptions of the structure-based reverse vaccinology par-
adigm, which prevented it from helping to develop an effective HIV-1 vaccine.
Front Immunol (2014) 5:593. doi:10.3389/fimmu.2014.00593
39. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s
pathways. Immunol Rev (2013) 254:225–44. doi:10.1111/imr.12075
40. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design
in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012)
30:423–33. doi:10.1038/nbt.2197
41. Ahlers JD. All eyes on the next generation of HIV vaccines: strategies for inducing
a broadly neutralizing antibody response. Discov Med (2014) 17:187–99.
42. Prabakaran P, Chen W, Dimitrov DS. The antibody germline/maturation
hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord
blood IgM repertoires. Front Immunol (2014) 5:398. doi:10.3389/fimmu.2014.
00398
43. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development.
Immunol Rev (2013) 254:295–304. doi:10.1111/imr.12073
44. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG,
et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous
SHIV challenges in rhesus monkeys. Cell (2013) 155:531–9. doi:10.1016/j.cell.
2013.09.061
45. Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nat Rev Microbiol
(2014) 12:765–71. doi:10.1038/nrmicro3360
46. Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The
canarypox virus vector ALVAC induces distinct cytokine responses compared to
the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol
(2014) 88:1809–14. doi:10.1128/JVI.02386-13
47. Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J,
Mejías-Pérez E, et al. Virological and immunological characterization of novel
NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric sol-
uble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. J Virol (2014)
89(2):970–88. doi:10.1128/JVI.02469-14
48. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L,
et al. Profound early control of highly pathogenic SIV by an effector memory
T-cell vaccine. Nature (2011) 473:523–7. doi:10.1038/nature10003
49. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al.
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.
Science (2013) 340:1237874. doi:10.1126/science.1237874
50. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine devel-
opment. Annu Rev Med (2012) 63:95–111. doi:10.1146/annurev-med-042010-
085643
51. Picker LJ. Are effector memory T cells the key to an effective HIV/AIDS vaccine?
EMBO Rep (2014) 15:820–1. doi:10.15252/embr.201439052
52. Fauci AS, Folkers GK, Marston HD. Ending the global HIV/AIDS pandemic:
the critical role of an HIV vaccine. Clin Infect Dis (2014) 59(Suppl 2):S80–4.
doi:10.1093/cid/ciu420
53. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al.
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Sci-
ence (2004) 303:316. doi:10.1126/science.1094620
54. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM,
et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med
(2012) 366:1275–8. doi:10.1056/NEJMoa1113425
55. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al.
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk
and declines soon after vaccination. Sci Transl Med (2014) 6:228ra39. doi:10.
1126/scitranslmed.3007730
Frontiers in Immunology | HIV and AIDS March 2015 | Volume 6 | Article 124 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Esparza Paradigm change in HIV vaccines
56. Veillette M, Désormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J,
et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted
by antibody-dependent cell-mediated cytotoxicity. J Virol (2014) 88:2633–44.
doi:10.1128/JVI.03230-13
57. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al.
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1
vaccine efficacy trial target multiple epitopes and preferentially use the VH1
gene family. J Virol (2012) 86:11521–32. doi:10.1128/JVI.01023-12
58. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, et al. Anti-
bodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV
challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci
U S A (2007) 104:17477–82. doi:10.1073/pnas.0707399104
59. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, et al.
Diverse specificity and effector function among human antibodies to HIV-1
envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S
A (2013) 110:E69–78. doi:10.1073/pnas.1217609110
60. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R,
et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxi-
city correlated with significantly reduced acute viremia in rhesus macaques chal-
lenged with SIVmac251. J Immunol (2005) 174:2185–9. doi:10.4049/jimmunol.
174.4.2185
61. Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, et al. A panel
of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ
receptors to define the role of effector functions in protection against HIV. J Virol
(2011) 85:10572–81. doi:10.1128/JVI.05541-11
62. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional anti-
bodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol (2014)
21:1023–36. doi:10.1128/CVI.00230-14
63. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013)
369:2083–92. doi:10.1056/NEJMoa1310566
64. P5 Partnership. Available from: http://www.vaccineenterprise.org/content/
P5Partnership (2014).
65. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kuna-
sol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vac-
cine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis
of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 12:531–7.
doi:10.1016/S1473-3099(12)70088-9
66. Esparza J. Understanding the efficacy variables of an HIV vaccine trial. Lancet
Infect Dis (2012) 12:499–500. doi:10.1016/S1473-3099(12)70117-2
67. Bregu M, Draper SJ, Hill AV, Greenwood BM. Accelerating vaccine development
and deployment: report of a Royal Society satellite meeting. Philos Trans R Soc
Lond B Biol Sci (2011) 366:2841–9. doi:10.1098/rstb.2011.0100
68. Nathanson N, Mathieson BJ. Biological considerations in the development
of a human immunodeficiency virus vaccine. J Infect Dis (2000) 182:579–89.
doi:10.1086/315707
69. Medawar PB. Advice to a Young Scientist. New York: Harper Colophon Books
(1979).
70. Miedema F. A brief history of HIV vaccine research: stepping back to the drawing
board? AIDS (2008) 22:1699–703. doi:10.1097/QAD.0b013e3283021a61
71. Kaplan D. Point: statistical analysis in NIH peer review – identifying innovation.
FASEB J (2007) 21:305–8. doi:10.1096/fj.07-0204ufm
72. Kaplan D, Lacetera N, Kaplan C. Sample size and precision in NIH peer review.
PLoS One (2008) 3:e2761. doi:10.1371/journal.pone.0002761
73. Parrott C. First grants for innovative AIDS vaccine research awarded. NIAID
AIDS Agenda (1997):5–7.
74. Culliton BJ. “Innovation” in AIDS vaccines. Nat Med (1997) 3:1181. doi:10.
1038/nm1097-1057a
75. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public
health. Grand challenges in global health. Science (2003) 302:398–9. doi:10.
1126/science.1091769
76. McEnery R. The AIDS vaccine field considers ways to encourage innovation and
recruit new minds to the effort. IAVI Rep (2009) 13:9–13.
77. Goodwin P. In: Report from the Wellcome-Gates Innovation Meeting. London
(2007).
78. Lu W, Chen S, Lai C, Guo W, Fu L, Andrieu JM. Induction of CD8+ regula-
tory T cells protects macaques against SIV challenge. Cell Rep (2012) 2:1736–46.
doi:10.1016/j.celrep.2012.11.016
79. Andrieu JM, Chen S, Lai C, Guo W, Lu W. Mucosal SIV vaccines com-
prising inactivated virus particles and bacterial adjuvants induce CD8(+) T-
regulatory cells that suppress SIV-positive CD4(+) T-cell activation and pre-
vent SIV infection in the macaque model. Front Immunol (2014) 5:297.
doi:10.3389/fimmu.2014.00297
80. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immu-
nization with HIV-1 gp41 subunit virosomes induces mucosal antibodies pro-
tecting nonhuman primates against vaginal SHIV challenges. Immunity (2011)
34:269–80. doi:10.1016/j.immuni.2011.01.015
81. Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen
M, Adler M, et al. Randomized phase I: safety, immunogenicity and mucosal
antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 pep-
tide on virosomes. PLoS One (2013) 8(2):e55438. doi:10.1371/journal.pone.
0055438
82. McElrath MJ. Standing guard at the mucosa. Immunity (2011) 34:146–8.
doi:10.1016/j.immuni.2011.02.014
83. Zhou M, Ruprecht RM. Are anti-HIV IgAs good guys or bad guys? Retrovirology
(2014) 11:109. doi:10.1186/PREACCEPT-1729873135143527
84. Vieillard V, Strominger JL, Debré P. NK cytotoxicity against CD4+ T cells during
HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand.
Proc Natl Acad Sci U S A (2005) 102:10981–6. doi:10.1073/pnas.0504315102
85. Plotkin SA. Problems in vaccine development. Monoclon Antib Immunodiagn
Immunother (2014) 33:166–7. doi:10.1089/mab.2014.0011
86. Sheppard HW, Dorman BP. Time for a systematic look at inactivated HIV vac-
cines. AIDS (2015) 29:125–7. doi:10.1097/QAD.0000000000000476
87. Esparza J, Van Regenmortel MH. More surprises in the development of an HIV
vaccine. Front Immunol (2014) 5:329. doi:10.3389/fimmu.2014.00329
88. Van Regenmortel MHV, Andrieu J-M, Dimitrov DS, Ensoli B, Hioe CE, Moog C,
et al. Paradigm changes and the future of HIV vaccines: a summary of a work-
shop held in Baltimore on 20 November 2013. J AIDS Clin Res (2014) 5:281.
doi:10.4172/2155-6113.1000281
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationship that could be construed
as a potential conflict of interest.
Received: 06 January 2015; accepted: 06 March 2015; published online: 18 March 2015.
Citation: Esparza J (2015) A new scientific paradigm may be needed to finally develop
an HIV vaccine. Front. Immunol. 6:124. doi: 10.3389/fimmu.2015.00124
This article was submitted to HIV and AIDS, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Esparza. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org March 2015 | Volume 6 | Article 124 | 7
